New Drug Update:

Brexpiprazole (Rexulti) and Pimavanserin (Nuplazid)

New antipsychotics with novel mechanisms

This month PL highlights two new antipsychotics recently on the market in the US.  The first, brexpiprazole, is a partial dopamine agonist, like aripiprazole, but with some differences.  The second, pimavanserin, is an “inverse serotonin agonist,” without any dopamine blockade at all, just approved...

To read the article, please click here or subscribe

Meet our expert EDITORIAL BOARD, composed of clinicians and researchers from around the world. 

Subscribe to the RSS feed below to follow our "What's new" blog posts